The stock of Ascendis Pharma A/S (NASDAQ:ASND) reached all time high today, Feb, 14 and still has $58.02 target or 7.00% above today’s $54.23 share price. This indicates more upside for the $2.01 billion company. This technical setup was reported by Barchart.com. If the $58.02 PT is reached, the company will be worth $140.35 million more. The stock increased 5.56% or $2.855 during the last trading session, reaching $54.225. About 171,900 shares traded or 9.74% up from the average. Ascendis Pharma A/S (NASDAQ:ASND) has risen 96.01% since February 14, 2017 and is uptrending. It has outperformed by 79.31% the S&P500.
Lakeland Financial Corporation operates as the bank holding firm for Lake City Bank that provides various financial services in Indiana. The company has market cap of $1.17 billion. The firm offers various deposit products, including noninterest bearing deposits; interest-bearing checking, savings, and money market deposits; and NOW and demand deposits. It has a 20.96 P/E ratio. It also provides commercial and industrial loans, commercial real estate and multi-family residential loans, agri-business and agricultural loans, and other commercial loans; and consumer 1-4 family mortgage loans and other consumer loans.
The stock increased 0.91% or $0.42 during the last trading session, reaching $46.73. About 30,313 shares traded. Lakeland Financial Corporation (LKFN) has risen 35.39% since February 14, 2017 and is uptrending. It has outperformed by 18.69% the S&P500.
Monarch Capital Management Inc holds 3.72% of its portfolio in Lakeland Financial Corporation for 204,952 shares. Neumeier Poma Investment Counsel Llc owns 417,180 shares or 2.12% of their US portfolio. Moreover, Walthausen & Co. Llc has 1.16% invested in the company for 255,691 shares. The Texas-based Vaughan Nelson Investment Management L.P. has invested 0.5% in the stock. 1St Source Bank, a Indiana-based fund reported 121,760 shares.
Since January 1, 0001, it had 3 buys, and 5 insider sales for $188,062 activity.
Among 7 analysts covering Ascendis Pharma (NASDAQ:ASND), 6 have Buy rating, 0 Sell and 1 Hold. Therefore 86% are positive. Ascendis Pharma has $65.0 highest and $28.0 lowest target. $49.57’s average target is -8.58% below currents $54.225 stock price. Ascendis Pharma had 17 analyst reports since September 26, 2016 according to SRatingsIntel. The rating was maintained by Wedbush with “Outperform” on Friday, March 24. The firm earned “Buy” rating on Tuesday, September 26 by Bank of America. The firm earned “Buy” rating on Wednesday, January 17 by J.P. Morgan. Wedbush maintained the shares of ASND in report on Friday, January 5 with “Buy” rating. The rating was initiated by Wedbush on Monday, September 26 with “Outperform”. As per Friday, September 22, the company rating was maintained by Credit Suisse. Wedbush maintained Ascendis Pharma A/S (NASDAQ:ASND) on Friday, September 22 with “Buy” rating. On Monday, September 11 the stock rating was maintained by Wedbush with “Buy”. Wedbush maintained it with “Buy” rating and $62.0 target in Thursday, September 28 report. The stock of Ascendis Pharma A/S (NASDAQ:ASND) earned “Buy” rating by Wells Fargo on Friday, September 22.